Lilly’s $2.9B Merida Acquisition Adds Immunology Diversification but Leaves Core Thesis Unchanged

What happened

Eli Lilly announced a $2.9 billion acquisition of Merida Biosciences, a private immunology biotech, expanding its pipeline beyond the dominant obesity and diabetes franchises. The deal adds early-stage immunology assets but is immaterial relative to Lilly’s $1.1 trillion market capitalization and second-quarter revenue of $22.97 billion. While it signals management’s intent to rebuild a diversified pharma portfolio, the acquisition does not address the central investment debate around tirzepatide net pricing, Foundayo oral uptake, or the retatrutide filing timeline. The purchase is likely cash-funded given Lilly’s $8.95 billion cash balance and modest net debt, and it introduces integration and development risk outside Lilly’s current core competency. Overall, the deal is a minor strategic step that may enhance long-term optionality but has no near-term impact on the company’s financials or the WAIT thesis.

Implication

The acquisition is too small to shift Lilly’s valuation or operating outlook, so it should not alter position sizing or trigger new buying. The primary investment checks remain third- and fourth-quarter 2026 realized price trends, Foundayo revenue acceleration after broad PBM and Medicare coverage, and the planned Q1 2027 retatrutide filing. While diversification into immunology could eventually reduce concentration risk, it does not offset the current dependence on Mounjaro and Zepbound, which represent 65% of revenue. At 39.4x P/E and 41.3x EV/EBITDA, the stock still lacks a margin of safety, and this deal does not create one. Therefore, investors should maintain a WAIT stance, using any price weakness toward $1,000 as a potential entry point only if the core thesis checks resolve positively.

Thesis delta

The thesis remains unchanged: Lilly’s investment case still hinges on obesity franchise economics, not on small bolt-on acquisitions. The Merida deal adds optionality but does not address the key uncertainties around net pricing, oral uptake, or next-generation pipeline timing. Consequently, the WAIT rating and valuation boundaries are unaffected.